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Abstract 
Background: Epidemiologic and laboratory evidence supports a role for cholesterol in prostate 
cancer (PC). Dietary saturated fat content impacts serum cholesterol levels. However, 
epidemiologic associations between saturated fat and PC aggressiveness are inconsistent. We 
hypothesized that high saturated fat intake would be associated with increased PC 
aggressiveness, and that statin use would modify this association. 
Methods: Of 1,854 PC cases in the North Carolina-Louisiana PC Project (PCaP), 321 (17%) 
were classified as high aggressive [Gleason sum ≥8, PSA >20 ng/ml, or (Gleason sum ≥7 and 
clinical stage T3-4)] or low/intermediate aggressive (all other cases). Using low/intermediate 
aggressive cases as the referent group, we examined the association between tertiles of total-fat 
adjusted saturated fat intake and high aggressive PC using logistic regression, overall and 
stratified by race and statin use. We examined total fat-adjusted polyunsaturated and 
monounsaturated fatty acids (PUFA and MUFA, respectively), trans fat, and cholesterol in 
secondary analysis. 
Results: High total fat-adjusted saturated fat intake was associated with an elevated odds ratio 
(OR) for aggressive PC (ORT3vs.T1 1.51; 95% CI 1.10-2.06; p-trend=0.009), with an attenuated 
association in statin users (ORT3vs.T1 1.16; 95% CI 0.67-2.01; p-trend=0.661) compared to non-
users (ORT3vs.T1 1.71; 95% CI 1.16-2.51; p-trend=0.053). High total fat-adjusted cholesterol 
intake was associated with aggressive PC in European Americans (ORT3vs.T1 1.62; 95% CI 1.02-
2.58; p-trend=0.056), but not African Americans (ORT3vs.T1 0.92; 95% CI 0.60-1.42; p-
trend=0.750). High total fat-adjusted PUFA was inversely associated with PC aggressiveness 
(ORT3vs.T1 0.75; 95% CI 0.55-1.03), although this was not significant. No associations were 
found between total fat-adjusted MUFA or trans fat and PC aggressiveness.  
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Conclusions: High total fat-adjusted saturated fat intake was associated with increased PC 
aggressiveness, with a suggestion of a stronger effect in men not using statins. The association 
between total fat-adjusted cholesterol intake and PC aggressiveness was most pronounced in 
European Americans.  
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Introduction 
Prostate cancer (PC) incidence rates vary more than 25-fold worldwide, and are highest in 
Western countries1. International variation in incidence rates is due in part to differences in 
screening practices between countries, but dietary factors may also play a role. Dietary fat intake, 
unlike other macronutrients, varies more than fivefold worldwide, and Western populations are 
among the highest consumers of saturated and trans fats, and cholesterol2.  
High fat dietary interventions in mouse models of PC drive tumor growth3,4, but several large 
prospective cohort studies found no association between different types of dietary fat and PC 
risk5-7. However, some evidence supports an association between elevated intake of saturated fat 
and increased PC aggressiveness8,9 and mortality8,10,11. Many prior studies were limited by 
incomplete assessment of potential confounders, including PC screening7. In addition, prior 
studies were primarily carried out in white populations, and so the impact of race on these 
associations remains poorly understood.  
Using the North Carolina-Louisiana PC Project (PCaP), a case-only study of incident PC in 
European Americans (EAs) and African Americans (AAs), we examined associations between 
dietary saturated fat intake and PC aggressiveness, overall and stratified by race. Dietary 
saturated fat intake impacts serum cholesterol levels12, and epidemiologic evidence supports a 
role for serum cholesterol and cholesterol-lowering statins in PC13,14. Indeed, we previously 
reported an inverse association between statin use and PC aggressiveness in PCaP15. As such, we 
explored the hypothesis that the association between saturated fat and PC aggressiveness would 
be weaker in men using statins to control serum cholesterol levels. In secondary analysis, we 
examined associations between total fat, polyunsaturated fatty acid (PUFA), monounsaturated 
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fatty acid (MUFA), trans fat, cholesterol intake and PC aggressiveness. 
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Materials and Methods 
Study population 
PCaP enrolled men 40-79 years of age diagnosed with PC on or after July 1, 2004, as previously 
described16. Research subjects self-identified as either AA/black or Caucasian/white (EA) in 
response to the open-ended question “What is your race?” Recruitment ended October 2007 in 
North Carolina (NC) and July 2009 in Louisiana (LA). Research protocols were approved by the 
institutional review boards at the University of North Carolina, Louisiana State University 
Health Services Center, and Department of Defense PC Research Program.  
Exposure assessment and explanatory variables 
PCaP research nurses administered questionnaires during an in-home visit approximately three 
months after diagnosis16. PC screening frequency was classified as a three-level variable (never 
screened, ≤1 PSA and/or digital rectal exam (DRE) per year, >1 PSA and/or DRE per year), as 
previously described15. The dietary assessment instrument was a modified National Cancer 
Institute (NCI) Diet History Questionnaire (DHQ)17,18 to which Southern US foods were added. 
Research subjects reported dietary intake during the 12 month period prior to PC diagnosis. 
Dietary intake of fatty acids and cholesterol was calculated using Diet*Calc analysis software 
(version 1.4.3, NCI, Applied Research Program, November 2005). No gold standard exists for 
validating calories from dietary fats and cholesterol. However, a comparative validation study 
indicated that energy-adjusted correlations between multiple 24 hour recalls and DHQ estimates 
were 0.68 for saturated fat, 0.61 for PUFA, 0.60 for MUFA, 0.66 for total fat, and 0.64 for 
cholesterol17. Research subjects gathered all prescription medications used in the 2-week period 
prior to interview and presented them to the research nurse at the time of interview for 
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documentation of current statin use. We previously reported an inverse association between 
statin use and PC aggressiveness, with no differences in this association by statin type or dose15. 
Therefore, we did not consider statin type or dose in the present analysis. 
Outcome assessment 
Clinical stage, biopsy Gleason sum, and serum PSA at diagnosis were abstracted from medical 
records. High aggressive PC, our outcome of interest, was defined as Gleason sum ≥8, or PSA 
>20 ng/ml, or (Gleason sum ≥7 and clinical stage T3-T4). Low/intermediate aggressive PC (all 
other cases) was used as the referent group for all analyses16. We excluded 85 research subjects 
lacking sufficient clinical data to define a PC aggressiveness category. We also excluded 
research subjects missing body mass index (BMI; n=21), PC screening frequency (n=221), 
smoking status (n=1), and those who reported implausibly low or high caloric intake (<800 or 
≥6,000 kcal/day, respectively; n=76). These exclusions resulted in 1,854 research subjects 
(n=993 EA and n=861 AA) for the present analysis. 
Statistical analysis 
We examined differences in patient and tumor characteristics between low/intermediate versus 
high aggressive PC cases, and across tertiles of total fat-adjusted saturated fat intake, using chi-
square tests for categorical variables, student’s t-tests for continuous, normally-distributed 
variables and rank sum tests for continuous non-normally distributed variables.  
Dietary variables were log transformed to improve normality. Saturated fat intake was adjusted 
for total fat intake using the residual method to examine the impact of saturated fat on PC 
aggressiveness independent of total fat intake19. Total fat-adjusted saturated fat intake was 
analyzed as a categorical variable, based on tertiles of the distribution among low/intermediate 
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aggressive PC cases. Logistic regression was used to estimate multivariable-adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) for associations between tertiles of total fat-adjusted 
saturated fat intake and PC aggressiveness (high vs. low/intermediate) using the lowest tertile 
(T1) as the referent. In secondary analysis, we explored race-specific tertiles of total fat-adjusted 
saturated fat intake. For multivariable analysis, we selected covariates using a directed acyclic 
graph and performed backwards selection to build our final model which included age 
(continuous), race (AA, EA), site (NC, LA), marital status (married/living as married, 
divorced/separated/widowed, single), BMI (continuous), statin use (yes, no), smoking status 
(never, former, current), PC screening frequency (never, ≤1 screening test per year, >1 screening 
test per year), energy intake (kcal; continuous), and energy-adjusted total fat intake (calculated 
using the residual method). Physical activity, education, income, Charleson comorbidity index, 
and family history of PC were dropped by backwards selection and therefore not included in the 
final model. Tests for trend of categorical variables were conducted by assigning each research 
subject the median value of their tertile of intake and modeling these values as a continuous 
variable. In secondary analysis, using the same method as described for total fat-adjusted 
saturated fat, we examined associations for tertiles of total fat-adjusted PUFA, MUFA, trans fat, 
and cholesterol intake and for tertiles of energy-adjusted total fat intake. We tested for 
interaction between race and dietary fat intake for predicting PC aggressiveness by incorporating 
a cross product term into the logistic regression model, and calculating the global p-value of the 
interaction term using the Wald test. We explored statin use as an effect modifier of associations 
between total fat-adjusted saturated fat intake and PC aggressiveness using models stratified by 
statin use. 
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Statistical analyses were performed using Stata 13.1 (Stata, Corp., College Station, TX, USA).  
Statistical significance was two-sided with p < 0.05. 
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Results 
Demographic characteristics by PC aggressiveness 
Research subjects with high aggressive PC tended to be older at diagnosis, and were more likely 
to be AA than EA (Table 1). High aggressive PC cases were less likely to be married/living as 
married, less likely to report a history of PC screening, and had lower education and income 
levels than low/intermediate cases. Alcohol intake and level of physical activity did not differ by 
PC aggressiveness (data not shown), but research subjects with high aggressive disease were 
more likely to be current smokers and obese, and less likely to be statin users.  
Saturated fat made up a larger percentage of total fat intake and PUFA made up a smaller 
percentage of total fat intake in research subjects with high versus low/intermediate aggressive 
PC, but there were no differences in percent MUFA or trans fat intake by PC aggressiveness 
(Table 1). Relative to research subjects with low/intermediate aggressive PC, those with high 
aggressive PC consumed a greater percentage of calories from total fat, and had higher 
cholesterol intake and higher daily energy intake. Dietary fat, cholesterol and energy intake by 
race are presented in Supplementary Table 1.  
Demographic and tumor characteristics by tertiles of total fat-adjusted saturated fat intake 
Age at diagnosis did not differ by saturated fat intake, but AAs consumed less saturated fat than 
EAs (Table 2). Research subjects who consumed greater amounts of saturated fat were more 
likely to have high aggressive PC, less likely to be married/living as married and less likely to 
report a history of PC screening. Level of education, income, smoking, and obesity status did not 
differ across tertiles of total fat-adjusted saturated fat intake.  
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Total fat-adjusted saturated fat, PUFA, MUFA and trans fat intake and PC aggressiveness 
Among 1,854 PC cases, 321 (n=175 AA and n=146 EA) had high aggressive disease. Relative to 
the lowest tertile, research subjects in the upper tertile of total fat-adjusted saturated fat intake 
had an elevated OR for high aggressive PC following adjustment for potential confounders 
(ORT3 vs. T1 1.51; 95% CI 1.10-2.06; p-trend=0.009; Table 3). Race-stratified analyses suggested 
that this effect was more pronounced in EAs (ORT3 vs. T1 1.96; 95% CI 1.23-3.12; p-trend=0.003) 
than AAs (ORT3 vs. T1 1.25; 95% CI 0.81-1.93; p-trend=0.321), but there was no significant 
interaction by race (p-interaction=0.452). We observed an inverse association between high total 
fat-adjusted PUFA intake and PC aggressiveness among all research subjects (ORT3 vs. T1 0.75; 
95% CI 0.55-1.03; p-trend=0.075), with a similar magnitude of inverse association in both EAs 
and AAs although neither overall nor race-stratified findings were statistically significant (Table 
3). There were no significant associations between total fat-adjusted MUFA or trans fat intake 
and PC aggressiveness, overall or in race-stratified analyses. The magnitude and direction of 
association between tertiles of energy-adjusted total fat intake and PC aggressiveness was similar 
to that reported for total fat-adjusted saturated fat intake (Table 3). The use of race-specific 
tertiles of dietary fat intake did not substantially impact our findings (Supplementary Table 2). 
Total fat-adjusted cholesterol intake and PC aggressiveness 
High total fat-adjusted cholesterol intake was associated with increased PC aggressiveness in 
EAs (ORT3 vs. T1 1.62; 95% CI 1.02-2.58; p-trend=0.056) but not AAs (ORT3 vs. T1 0.92; 95% CI 
0.60-1.42; p-trend=0.750), although the interaction by race was not statistically significant (p-
interaction=0.244). Analyses using race-specific tertiles of total fat-adjusted cholesterol intake 
produced similar findings (Supplementary Table 2). 
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Statin use as an effect modifier of the saturated fat - PC aggressiveness association 
Analyses stratified by statin use showed that research subjects in the upper tertile of total fat-
adjusted saturated fat intake had an elevated OR for high aggressive PC regardless of statin use 
status. However, there was a weaker association in statin users (ORT3 vs. T1 1.16; 95% CI 0.67-
2.01; p-trend=0.661) compared to non-users (ORT3 vs. T1 1.71; 95% CI 1.16-2.51; p-trend=0.053; 
Table 4), although there was no significant interaction by statin use (p-interaction=0.430).
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Discussion 
Using data from the population-based, case-only PCaP, we report that elevated dietary intake of 
saturated fat was associated with increased PC aggressiveness. In secondary analysis, we found 
that higher total fat intake was also associated with more aggressive disease. Although there was 
no strong evidence for racial differences in these associations, effect estimates for total and 
saturated fat were larger in EAs relative to AAs, and high dietary cholesterol was associated with 
higher PC aggressiveness only in EAs. These findings support a role for dietary fat intake in PC 
aggressiveness in both EA and AA men, although future studies are required to test the 
suggestion that these associations may be stronger in EAs. 
Relatively few studies to date have examined associations between dietary fat and PC by race. 
The prospective Multiethnic Cohort (MEC) study reported no associations between any type of 
dietary fat or cholesterol intake and either total or aggressive PC risk in any of five racial/ethnic 
groups examined5. A case-control study of four different racial/ethnic groups in North America 
reported a positive association between saturated fat intake and PC risk in both EAs and AAs20. 
Two studies indirectly assessed saturated fat intake by measuring red meat and animal fat 
consumption; one multi-center case-control study in the US showed a positive association 
between animal fat intake and aggressive disease in both EAs and AAs21, while the prospective 
Cancer Prevention Study II reported stronger associations between red meat consumption and PC 
risk in AAs22. Collectively, the findings of these prior studies and those of the present analysis do 
not provide strong evidence for racial differences in associations between dietary fat and 
cholesterol intake and PC aggressiveness and if a racial difference exists, the difference appears 
small. 
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A number of biologic mechanisms may contribute to associations between dietary fat and PC 
aggressiveness. High fat diets can modulate androgen signaling23, up-regulate the insulin-like 
growth factor (IGF) pathway, and increase prostate inflammation, thereby promoting PC 
growth24,25. Moreover, saturated fat intake is an important dietary determinant of serum 
cholesterol levels12,26. Epidemiologic data support a positive association between high serum 
cholesterol and PC aggressiveness27 and an inverse association between statin use and PC 
aggressiveness15,28. If saturated fat intake promotes PC aggressiveness by raising serum 
cholesterol levels, the association between saturated fat and PC aggressiveness should be 
attenuated in individuals using statins to control serum cholesterol levels. We observed a weaker 
magnitude of effect in statin users, but found no strong evidence to support statin use as an effect 
modifier of the saturated fat-PC aggressiveness association. These findings may reflect the 
complex relationship between saturated fat and PC aggressiveness, given multiple determinants 
(both dietary and genetic) of serum cholesterol levels, in addition to the aforementioned 
cholesterol-independent mechanisms by which saturated fat may impact PC aggressiveness.  
Epidemiologic evidence supporting an association between PUFA intake and PC aggressiveness 
is sparse and inconsistent. Individual studies have reported positive6, inverse29 and null 
associations8, and a recent meta-analysis reported a null association between PUFA intake and 
risk of both total and aggressive PC7. Furthermore, a recent systematic review found no 
consistent role for fish oil, an important source of omega-3 PUFAs, in reducing PC incidence, 
aggressiveness, or mortality30. In the present study, although the direction of association between 
PUFA intake and PC aggressiveness was inverse, these findings were not statistically significant 
either overall or in race-stratified analysis.  
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Several limitations of this study should be considered. First, although we used a validated FFQ in 
the present study, FFQs are subject to recall bias and may be influenced by case status of the 
research subject. However, given that all of our research subjects were incident PC cases, this 
potential source of bias is likely to be minimal. Furthermore, the use of rapid case ascertainment 
limited the time between diagnosis and enrollment in PCaP, thus reducing the likelihood of bias 
from time or treatment. Second, serum levels of fatty acids and cholesterol were not measured in 
PCaP as measurements at the time of diagnosis may be impacted by presence of PC, raising 
concerns about reverse causality31. Measurement of dietary fat intake using a validated FFQ may 
be less subject to this potential source of bias. These limitations are balanced by several 
important strengths. All types of dietary fat and cholesterol were adjusted for total fat intake 
using the residual method, and models were adjusted for energy-adjusted total fat intake and 
energy intake. This approach separated the effects of each fat type from total fat on PC 
aggressiveness while controlling for energy intake. Finally, an important strength of this study is 
the inclusion of both EAs and AAs in similar proportions, in addition to our comprehensive 
assessment of clinical and demographic characteristics and adjustment for these potential 
confounders in our analysis. 
In summary, elevated dietary intake of saturated and total fat were associated with increased PC 
aggressiveness. Although we observed no statistically significant racial differences in these 
associations, high saturated and total fat intake were suggestively more strongly associated with 
PC aggressiveness in EAs, and cholesterol was associated with higher PC aggressiveness in EAs 
but not in AAs. Established PC risk factors, including older age, AA race, and family history of 
PC, are not modifiable. If confirmed, these findings may be relevant for aggressive PC 
prevention efforts, given that dietary fat content and composition are modifiable risk factors.
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Table 1: Characteristics of research subjects with low/intermediate versus high aggressive prostate cancer  
 Prostate cancer aggressiveness  
 Low/intermediate High p-value 
Age at diagnosis, mean (SD) 62.6 (7.9) 64.7 (7.6) <0.0001 
Race, n (%)    
European American 847 (55) 146 (45) 0.001 African American 686 (45) 175 (55) 
Site, n (%)    
North Carolina 751 (49) 138 (43) 0.050 Louisiana 782 (51) 183 (57) 
Marital status, n (%)    
Single/never married 58 (4) 21 (7) 
<0.0001 Divorced/separated/widowed 260 (17) 82 (26) 
Married/living as married 1,215 (79) 218 (68) 
Screening frequency, n (%)    
Never 234 (15) 98 (31) 
<0.0001 ≤1 PSA/DRE test per year 947 (62) 167 (52) 
>1 PSA/DRE test per year 352 (23) 56 (17) 
Education, n (%)    
Less than high school 249 (16) 88 (27) 
<0.0001 High school graduate 378 (25) 69 (22) 
College graduate or some college 905 (59) 164 (51) 
Incomeǂ, (%)    
<$20,000 246 (17) 89 (31) 
<0.0001 $20,000-$50,000 476 (34) 95 (33) $50,000-$80,000 309 (22) 47 (16) 
>$80,000 378 (27) 57 (20) 
Smoking status, n (%)    
Never 537 (35) 89 (28) 
<0.0001 Past 796 (52) 165 (51) 
Current 200 (13) 67 (21) 
BMI (kg/m2), n (%)    
<25 287 (19) 55 (17) 
0.041 25-30 678 (44) 123 (38) 
≥30 568 (37) 143 (45) 
Statin use, n (%)    
No 932 (61) 214 (67) 0.049 Yes 601 (39) 107 (33) 
Saturated fat (% total fat), mean (SD) 31.0 (4.5) 31.9 (4.7) 0.001 
PUFA (% total fat), mean (SD) 23.3 (4.2) 22.5 (4.4) 0.005 
MUFA (% total fat), mean (SD) 38.2 (2.6) 38.1 (2.4) 0.747 
Trans fat (% total fat), mean (SD) 6.2 (1.7) 6.3 (1.7) 0.409 
Total fat (% energy), mean (SD) 34.0 (6.8) 34.9 (7.1) 0.040 
Cholesterol (mg/day), median (IQR) 272 (186-371) 304 (222-421) 0.0001 
Energy intake (kcal/day), median (IQR) 2,253 (1,713-3,000) 2,450 (1,802-3,324) 0.006 
22 
 
ǂn=41 did not know their income and n=116 refused to answer this question; n=1 was missing education 
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Table 2: Characteristics of research subjects by tertile of total fat-adjusted saturated fat intake 
 Total fat-adjusted saturated fatǂ   
 T1 T2 T3 p value 
Age at diagnosis, mean (SD) 63.5 (7.6) 62.0 (7.9) 63.4 (8.2) 0.189 
Race, n (%)     
European American 288 (48) 306 (50) 399 (62) <0.0001 African American 309 (52) 304 (50) 248 (38) 
Site, n (%)     
North Carolina 275 (46) 307 (50) 307 (47) 0.317 Louisiana 322 (54) 303 (50) 340 (53) 
Aggressive prostate cancer, n (%)     
Low/Intermediate 511 (86) 511 (84) 511 (79) 0.006 High 86 (14) 99 (16) 136 (21) 
Marital status, n (%)     
Single/never married 19 (3) 31 (5) 29 (5) 
<0.0001 Divorced/separated/widowed 86 (14) 104 (17) 152 (23) 
Married/living as married 492 (82) 475 (78) 466 (72) 
Screening frequency, n (%)     
Never 83 (14) 115 (19) 134 (21) 
0.029 <1 PSA/DRE test per year 381 (64) 358 (59) 375 (58) 
>1 PSA/DRE test per year 133 (22) 137 (22) 138 (21) 
Education, n (%)     
Less than high school 102 (17) 102 (17) 133 (21) 
0.355 High school graduate 140 (24) 150 (25) 157 (24) 
College graduate or some college 355 (59) 357 (58) 357 (55) 
Incomeǂ, n (%)     
<$20,000 98 (18) 103 (18) 134 (23) 
0.340 $20,000-$50,000 186 (34) 190 (34) 195 (33) $50,000-$80,000 115 (21) 123 (22) 118 (20) 
>$80,000 150 (27) 148 (26) 137 (24) 
Smoking status, n (%)     
Never 214 (36) 203 (33) 209 (32) 
0.093 Past 316 (53) 314 (52) 331 (51) 
Current 67 (11) 93 (15) 107 (17) 
BMI (kg/m2), n (%)     
<25 109 (18) 111 (18) 122 (19) 
0.586 25-30 273 (46) 254 (42) 274 (42) 
≥30 215 (36) 245 (40) 251 (39) 
Statin use, n (%)     
No 384 (64) 353 (58) 409 (63) 0.046 Yes 213 (36) 257 (42) 238 (37) 
ǂn=41 did not know their income and n=116 refused to answer this question; n=1 was missing education 
 ǂsaturated fat was adjusted for total fat intake using the residual method
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Table 3: Odds ratios for aggressive prostate cancer according to tertiles of total fat-adjusted dietary fat and cholesterol intake, overall and 
stratified by race 
 All  European American African American 
 
n, 
low/intermediate 
(high aggressive) 
OR* 
(95% CI) 
n, 
low/intermediate 
(high aggressive) 
OR* 
(95% CI) 
n, 
low/intermediate 
(high aggressive) 
OR* 
(95% CI) 
Saturated fatǂ       
T1 511 (86) 1.00 (ref) 256 (32) 1.00 (ref) 255 (54) 1.00 (ref) 
T2 511 (99) 1.17 (0.84-1.62) 268 (38) 1.23 (0.73-2.07) 243 (61) 1.05 (0.68-1.63) 
T3 511 (136) 1.51 (1.10-2.06) 323 (76) 1.96 (1.23-3.12) 188 (60) 1.25 (0.81-1.93) 
p-trend  0.009  0.003  0.321 
PUFAǂ       
T1 511 (126) 1.00 (ref) 314 (61) 1.00 (ref) 197 (65) 1.00 (ref) 
T2 511 (106) 0.89 (0.66-1.20) 262 (47) 0.99 (0.64-1.53) 249 (59) 0.78 (0.51-1.19) 
T3 511 (89) 0.75 (0.55-1.03) 271 (38) 0.70 (0.44-1.11) 240 (51) 0.73 (0.48-1.13) 
p-trend  0.075  0.154  0.157 
MUFAǂ       
T1 511 (107) 1.00 (ref) 297 (53) 1.00 (ref) 214 (54) 1.00 (ref) 
T2 511 (118) 1.03 (0.77-1.40) 282 (56) 1.07 (0.70-1.65) 229 (62) 0.95 (0.61-1.46) 
T3 511 (96) 0.89 (0.65-1.22) 268 (37) 0.81 (0.50-1.30) 243 (59) 0.99 (0.64-1.53) 
p-trend  0.509  0.436  0.956 
Trans fatǂ       
T1 511 (101) 1.00 (ref) 332 (58) 1.00 (ref) 179 (43) 1.00 (ref) 
T2 511 (109) 0.98 (0.72-1.33) 270 (55) 1.20 (0.79-1.83) 241 (54) 0.82 (0.51-1.30) 
T3 511 (111) 0.97 (0.71-1.33) 245 (33) 0.76 (0.47-1.23) 266 (78) 1.09 (0.70-1.70) 
p-trend  0.857  0.376  0.584 
Total fatǂ       
T1 511 (96) 1.00 (ref) 230 (28) 1.00 (ref) 281 (68) 1.00 (ref) 
T2 511 (99) 1.12 (0.82-1.55) 287 (42) 1.18 (0.70-1.99) 224 (57) 1.14 (0.75-1.72) 
T3 511 (126) 1.48 (1.08-2.02) 330 (76) 1.84 (1.13-2.98) 181 (50) 1.19 (0.77-1.83) 
p-trend  0.016  0.010  0.408 
Cholesterolǂ       
T1 511 (94) 1.00 (ref) 319 (49) 1.00 (ref) 192 (45) 1.00 (ref) 
T2 511 (98) 0.92 (0.66-1.26) 311 (47) 1.02 (0.65-1.59) 200 (51) 0.85 (0.53-1.36) 
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T3 511 (129) 1.16 (0.85-1.58) 217 (50) 1.62 (1.02-2.58) 294 (79) 0.92 (0.60-1.42) 
p-trend  0.369  0.056  0.750 
*adjusted for age, race (except for analyses stratified by race), site, marital status, BMI, statin use, smoking status, prostate cancer screening 
frequency, energy-adjusted total fat intake (except for total fat analyses) and energy intake 
ǂadjusted for total fat intake using the residual method (with the exception of total fat which was adjusted for energy intake using the residual 
method)
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Table 4: Associations between tertiles of total fat-adjusted saturated fat intake and prostate cancer 
aggressiveness stratified by statin use  
 Statin non-users Statin users 
 
n, 
low/intermediate 
(high aggressive) 
OR* (95%CI) 
n, 
low/intermediate 
(high aggressive) 
OR* (95%CI) 
Saturated fatǂ      
T1 328 (56) 1.00 (ref) 183 (30) 1.00 (ref) 
T2 292 (61) 1.21 (0.80-1.84) 219 (38) 1.03 (0.60-1.78) 
T3 312 (97) 1.71 (1.16-2.51) 199 (39) 1.16 (0.67-2.01) 
p-trend  0.053  0.661 
*adjusted for age, race, site, marital status, BMI, smoking status, prostate cancer screening frequency, 
energy-adjusted total fat intake, and energy intake 
ǂsaturated fat was adjusted for total fat intake using the residual method 
 
 
 
 
